Stocks · News reference
TriSalus Life Sciences secured FDA clearance for its TriNav Advance device, but shares face critical resistance levels amid a recent slide.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
TriSalus Life Sciences announced that its CEO and CFO will participate in the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum.
TriSalus Life Sciences (NASDAQ:TLSI) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time
U.S. stocks fell Wednesday, led by a 1.1% Nasdaq drop. Cintas beat estimates and raised guidance; oil gained while gold, silver and copper declined.
U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.
Analysts raised targets for Meta, Microsoft, Valero and others; Microsoft upgraded to Buy, while KB Home and RTX targets fell.